3PO has been used as a 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3(PFKFB3) inhibitor to study its effect on cell viability loss, apoptosis, and necroptosis in colorectal cancer cells. It has also been used as a PFKFB3 inhibitor to inhibit glycolysis and study its effects on cell viability and reactive oxygen species (ROS) production in trabectedin (TRB) and lurbinectedin (LUR) treated human macrophages (hMFs).
Biochem/physiol Actions
3PO is a potent and selective inhibitor of PFKFB3 (6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase) that reduces glycolytic flux and suppresses glucose uptake. 3PO is selectively cytostatic to transformed cells and suppresses the growth of established tumor in mice.
3PO is a potent and selective inhibitor of PFKFB3 (6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase).
Inhibition of glycolysis by PFKFB3 blockade mediated by 3PO reduced pathological angiogenesis in cancer and inflammation. 3PO aids in the regulation of endothelial proliferation and migration. It also reduces pro-inflammatory activation of endothelial cells and experimental inflammation in vivo. Therefore, it may be a potential therapeutic for treating chronic inflammation. Its anti-inflammatory activity in human endothelial cells is independent of its target PFKFB3.